secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-038742
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango doses first patients in TNG462, TNG260 trials; CSO Alan Huang to depart; Q2 net loss narrows
--------------------------------------------------------------------------------

- First patient dosed in phase 1/2 of TNG462 (next-gen PRMT5 inhibitor) for MTAP-deleted tumors.
- First patient dosed in phase 1/2 of TNG260 (CoREST inhibitor) with pembrolizumab for STK11-mutant cancers.
- CSO Alan Huang to step down Oct 2023; Jannik Andersen promoted to CSO effective Oct 9, 2023.
- Cash $310.7M as of June 30, 2023, sufficient to fund operations into 2026.
- Q2 2023 net loss $20.7M ($0.23/sh) vs $24.9M ($0.28/sh) in Q2 2022; license revenue $5.0M from Gilead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/0000950170-23-038742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer